Download PDF
Semin Neurol 2023; 43(04): 553-561
DOI: 10.1055/s-0043-1771468
Review Article

The Role of Helicobacter pylori and Small Intestinal Bacterial Overgrowth in Parkinson's Disease

Maria Belen Justich
1   Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
2   Division of Neurology, University of Toronto, Toronto, Ontario, Canada
,
Olga L. Rojas
3   Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada
4   Department of Immunology, University of Toronto, Ontario, Canada
,
Alfonso Fasano
1   Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
2   Division of Neurology, University of Toronto, Toronto, Ontario, Canada
5   Department of Parkinson's Disease and Movement Disorders Rehabilitation, Moriggia-Pelascini Hospital – Gravedona ed Uniti, Como, Italy
› Author Affiliations Funding This work was supported by the University of Toronto and University Health Network Chair in Neuromodulation.
› Further Information
    Permissions and Reprints

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder whose etiology remains largely unexplained. Several studies have aimed to describe a causative effect in the interactions between the gastrointestinal tract and the brain, for both PD pathogenesis and disease course. However, the results have been controversial. Helicobacter pylori and small intestinal bacterial overgrowth (SIBO) are theorized to be agents capable of triggering chronic proinflammatory changes with a possible neurotoxic effect, as well as a cause of erratic L-dopa response in PD patients. This review evaluates the individual and possibly synergistic influence of H. pylori and SIBO on PD, to provide an opportunity to consider prospective therapeutic approaches.

Keywords

Parkinson's disease - Helicobacter pylori - small intestinal bacterial overgrowth


Publication History

Article published online:
10 August 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Kalia LV, Lang AE. Parkinson's disease. Lancet 2015; 386 (9996): 896-912
    CrossrefPubMedGoogle Scholar
  • 2 Berg D, Adler CH, Bloem BR. et al. Movement disorder society criteria for clinically established early Parkinson's disease. Mov Disord 2018; 33 (10) 1643-1646
    CrossrefPubMedGoogle Scholar
  • 3 Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB. MDS Task Force on the Definition of Parkinson's Disease. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord 2019; 34 (10) 1464-1470
    CrossrefPubMedGoogle Scholar
  • 4 Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26 (03) 399-406
    CrossrefPubMedGoogle Scholar
  • 5 Nalls MA, Blauwendraat C, Vallerga CL. et al; 23andMe Research Team, System Genomics of Parkinson's Disease Consortium, International Parkinson's Disease Genomics Consortium. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019; 18 (12) 1091-1102
    CrossrefPubMedGoogle Scholar
  • 6 Dănău A, Dumitrescu L, Lefter A, Tulbă D, Popescu BO. Small intestinal bacterial overgrowth as potential therapeutic target in Parkinson's disease. Int J Mol Sci 2021; 22 (21) 11663
    CrossrefPubMedGoogle Scholar
  • 7 Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2015; 14 (06) 625-639
    CrossrefPubMedGoogle Scholar
  • 8 Bjornestad A, Forsaa EB, Pedersen KF, Tysnes OB, Larsen JP, Alves G. Risk and course of motor complications in a population-based incident Parkinson's disease cohort. Parkinsonism Relat Disord 2016; 22: 48-53
    CrossrefPubMedGoogle Scholar
  • 9 Levine KS, Leonard HL, Blauwendraat C. et al. Virus exposure and neurodegenerative disease risk across national biobanks. Neuron 2023; 111 (07) 1086-1093.e2
    CrossrefPubMedGoogle Scholar
  • 10 Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33 (06) 599-614
    CrossrefPubMedGoogle Scholar
  • 11 Pont-Sunyer C, Hotter A, Gaig C. et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord 2015; 30 (02) 229-237
    CrossrefPubMedGoogle Scholar
  • 12 Passali GC, Bove F, Vargiu L. et al. New olfactometric findings in Parkinson's disease. Clin Otolaryngol 2017; 42 (04) 837-843
    CrossrefPubMedGoogle Scholar
  • 13 Lin CH, Lin JW, Liu YC, Chang CH, Wu RM. Risk of Parkinson's disease following severe constipation: a nationwide population-based cohort study. Parkinsonism Relat Disord 2014; 20 (12) 1371-1375
    CrossrefPubMedGoogle Scholar
  • 14 Svensson E, Horváth-Puhó E, Thomsen RW. et al. Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol 2015; 78 (04) 522-529
    CrossrefPubMedGoogle Scholar
  • 15 Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection. Helicobacter 2017; 22 (Suppl. 01) DOI: 10.1111/hel.12403.
    CrossrefPubMedGoogle Scholar
  • 16 Cryan JF, O'Riordan KJ, Cowan CSM. et al. The microbiota-gut-brain axis. Physiol Rev 2019; 99 (04) 1877-2013
    CrossrefPubMedGoogle Scholar
  • 17 Chen Z, Maqbool J, Sajid F, Hussain G, Sun T. Human gut microbiota and its association with pathogenesis and treatments of neurodegenerative diseases. Microb Pathog 2021; 150: 104675
    CrossrefPubMedGoogle Scholar
  • 18 Scheperjans F, Aho V, Pereira PAB. et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2015; 30 (03) 350-358
    CrossrefPubMedGoogle Scholar
  • 19 Forsyth CB, Shannon KM, Kordower JH. et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 2011; 6 (12) e28032
    CrossrefPubMedGoogle Scholar
  • 20 Hasegawa S, Goto S, Tsuji H. et al. (2015). Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson's Disease. PloS one 2015; 10 (11) e0142164 DOI: 10.1371/journal.pone.0142164.
    CrossrefPubMedGoogle Scholar
  • 21 Reich N, Hölscher C. Acylated ghrelin as a multi-targeted therapy for Alzheimer's and Parkinson's disease. Front Neurosci 2020; 14: 614828
    CrossrefPubMedGoogle Scholar
  • 22 Murros KE, Huynh VA, Takala TM, Saris PEJ. Desulfovibrio bacteria are associated with Parkinson's disease. Front Cell Infect Microbiol 2021; 11: 652617
    CrossrefPubMedGoogle Scholar
  • 23 Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: small intestinal bacterial overgrowth. Am J Gastroenterol 2020; 115 (02) 165-178
    CrossrefPubMedGoogle Scholar
  • 24 Sampson TR, Debelius JW, Thron T. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell 2016; 167 (06) 1469-1480.e12
    CrossrefPubMedGoogle Scholar
  • 25 Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2 (09) 416-422
    CrossrefPubMedGoogle Scholar
  • 26 Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012; 76 (01) 16-32
    CrossrefPubMedGoogle Scholar
  • 27 Smeyne RJ, Noyce AJ, Byrne M, Savica R, Marras C. Infection and risk of Parkinson's disease. J Parkinsons Dis 2021; 11 (01) 31-43
    CrossrefPubMedGoogle Scholar
  • 28 Fitzpatrick Z, Frazer G, Ferro A. et al. Gut-educated IgA plasma cells defend the meningeal venous sinuses. Nature 2020; 587 (7834): 472-476
    CrossrefPubMedGoogle Scholar
  • 29 Pröbstel AK, Zhou X, Baumann R. et al. Gut microbiota-specific IgA+ B cells traffic to the CNS in active multiple sclerosis. Sci Immunol 2020; 5 (53) eabc7191
    CrossrefPubMedGoogle Scholar
  • 30 Benveniste EN, Benos DJ. TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function. FASEB J 1995; 9 (15) 1577-1584
    CrossrefPubMedGoogle Scholar
  • 31 Sulzer D, Alcalay RN, Garretti F. et al. T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature 2017; 546 (7660): 656-661
    CrossrefPubMedGoogle Scholar
  • 32 Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007; 208 (01) 1-25
    CrossrefPubMedGoogle Scholar
  • 33 Hooi JKY, Lai WY, Ng WK. et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017; 153 (02) 420-429
    CrossrefPubMedGoogle Scholar
  • 34 Lolekha P, Sriphanom T, Vilaichone RK. Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson's disease patients: a prospective cohort study (HP-PD trial). PLoS One 2021; 16 (05) e0251042
    CrossrefPubMedGoogle Scholar
  • 35 Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol 2012; 19 (06) 864-869
    CrossrefPubMedGoogle Scholar
  • 36 Chen L, Xu W, Lee A. et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial. EBioMedicine 2018; 35: 87-96
    CrossrefPubMedGoogle Scholar
  • 37 Liou JM, Chen CC, Chang CM. et al; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis 2019; 19 (10) 1109-1120
    CrossrefPubMedGoogle Scholar
  • 38 Shen X, Yang H, Wu Y, Zhang D, Jiang H. Meta-analysis: association of Helicobacter pylori infection with Parkinson's diseases. Helicobacter 2017; 22 (05) e12398
    CrossrefPubMedGoogle Scholar
  • 39 Budzyński J, Kłopocka M. Brain-gut axis in the pathogenesis of Helicobacter pylori infection. World J Gastroenterol 2014; 20 (18) 5212-5225
    CrossrefPubMedGoogle Scholar
  • 40 Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol 2015; 21 (37) 10609-10620
    CrossrefPubMedGoogle Scholar
  • 41 Dobbs RJ, Dobbs SM, Weller C. et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 2005; 10 (04) 267-275
    CrossrefPubMedGoogle Scholar
  • 42 Dobbs RJ, Dobbs SM, Weller C. et al. Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. Helicobacter 2008; 13 (05) 309-322
    CrossrefPubMedGoogle Scholar
  • 43 Liu B, Gao HM, Hong JS. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 2003; 111 (08) 1065-1073
    CrossrefPubMedGoogle Scholar
  • 44 Kountouras J, Zavos C, Polyzos SA. et al. Helicobacter pylori infection and Parkinson's disease: apoptosis as an underlying common contributor. Eur J Neurol 2012; 19 (06) e56-e56
    CrossrefPubMedGoogle Scholar
  • 45 Nyholm D, Hellström PM. Effects of Helicobacter pylori on Levodopa pharmacokinetics. J Parkinsons Dis 2021; 11 (01) 61-69
    CrossrefPubMedGoogle Scholar
  • 46 Fiorini G, Bland JM, Hughes E, Castelli V, Vaira D. A systematic review on drugs absorption modifications after eradication in Helicobacter pylori positive patients undergoing replacement therapy. J Gastrointestin Liver Dis 2015; 24 (01) 95-100 , 1, 100
    CrossrefPubMedGoogle Scholar
  • 47 Fotiadis D, Kanai Y, Palacín M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med 2013; 34 (2-3): 139-158
    CrossrefPubMedGoogle Scholar
  • 48 Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 2008; 23 (12) 1696-1700
    CrossrefPubMedGoogle Scholar
  • 49 Zhong R, Chen Q, Zhang X, Li M, Lin W. Helicobacter pylori infection is associated with a poor response to levodopa in patients with Parkinson's disease: a systematic review and meta-analysis. J Neurol 2022; 269 (02) 703-711
    CrossrefPubMedGoogle Scholar
  • 50 Pierantozzi M, Pietroiusti A, Brusa L. et al. Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations. Neurology 2006; 66 (12) 1824-1829
    CrossrefPubMedGoogle Scholar
  • 51 Dardiotis E, Tsouris Z, Mentis AA. et al. H. pylori and Parkinson's disease: meta-analyses including clinical severity. Clin Neurol Neurosurg 2018; 175: 16-24
    CrossrefPubMedGoogle Scholar
  • 52 Narożańska E, Białecka M, Adamiak-Giera U. et al. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection. Clin Neuropharmacol 2014; 37 (04) 96-99
    CrossrefPubMedGoogle Scholar
  • 53 Malfertheiner P, Megraud F, O'Morain CA. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (01) 6-30
    CrossrefPubMedGoogle Scholar
  • 54 Grace E, Shaw C, Whelan K, Andreyev HJN. Review article: small intestinal bacterial overgrowth – prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 2013; 38 (07) 674-688
    CrossrefPubMedGoogle Scholar
  • 55 Li X, Feng X, Jiang Z, Jiang Z. Association of small intestinal bacterial overgrowth with Parkinson's disease: a systematic review and meta-analysis. Gut Pathog 2021; 13 (01) 25
    CrossrefPubMedGoogle Scholar
  • 56 Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y) 2007; 3 (02) 112-122
    PubMedGoogle Scholar
  • 57 Fasano A, Bove F, Gabrielli M. et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013; 28 (09) 1241-1249
    CrossrefPubMedGoogle Scholar
  • 58 Tan AH, Mahadeva S, Thalha AM. et al. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord 2014; 20 (05) 535-540
    CrossrefPubMedGoogle Scholar
  • 59 Bhattacharyya D, Bhunia A. Gut-brain axis in Parkinson's disease etiology: the role of lipopolysaccharide. Chem Phys Lipids 2021; 235: 105029
    CrossrefPubMedGoogle Scholar
  • 60 Kelly LP, Carvey PM, Keshavarzian A. et al. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord 2014; 29 (08) 999-1009
    CrossrefPubMedGoogle Scholar
  • 61 Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 2019; 364 (6445): eaau6323
    CrossrefPubMedGoogle Scholar
  • 62 van Kessel SP, Frye AK, El-Gendy AO. et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun 2019; 10 (01) 310
    CrossrefPubMedGoogle Scholar
  • 63 Said HM. Physiology of the Gastrointestinal Tract. Academic Press; 2018
    Google Scholar
  • 64 Gasbarrini A, Lauritano EC, Gabrielli M. et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 2007; 25 (03) 237-240
    CrossrefPubMedGoogle Scholar
  • 65 Lauritano EC, Gabrielli M, Scarpellini E. et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008; 103 (08) 2031-2035
    CrossrefPubMedGoogle Scholar
  • 66 Tan AH, Lim SY, Mahadeva S. et al. Helicobacter pylori eradication in Parkinson's disease: a randomized placebo-controlled trial. Mov Disord 2020; 35 (12) 2250-2260
    CrossrefPubMedGoogle Scholar
  • 67 Dobbs SM, Dobbs RJ, Weller C. et al. Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota. J Neurovirol 2016; 22 (01) 22-32
    CrossrefPubMedGoogle Scholar
  • 68 Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson's disease. npj Parkinsons Dis 2022; 8 (01) 56
    PubMedGoogle Scholar
  • 69 Sørensen CG, Karlsson WK, Amin FM, Lindelof M. Metronidazole-induced encephalopathy: a systematic review. J Neurol 2020; 267 (01) 1-13
    CrossrefPubMedGoogle Scholar
  • 70 Tandan M, Cormican M, Vellinga A. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: a systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents 2018; 52 (05) 529-540
    CrossrefPubMedGoogle Scholar
  • 71 de Moraes Andrade PV, Monteiro YM, Chehter EZ. Third-line and rescue therapy for refractory Helicobacter pylori infection: a systematic review. World J Gastroenterol 2023; 29 (02) 390-409
    CrossrefPubMedGoogle Scholar